Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Stock analysts at HC Wainwright lowered their FY2024 EPS estimates for shares of Invivyd in a report issued on Wednesday, November 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.63) per share for the year, down from their previous estimate of ($1.15). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Invivyd's current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Invivyd's Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.
A number of other analysts also recently weighed in on IVVD. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a report on Wednesday. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th.
Check Out Our Latest Stock Report on Invivyd
Invivyd Stock Up 1.0 %
Shares of IVVD traded up $0.01 during mid-day trading on Friday, hitting $0.71. 384,933 shares of the company's stock were exchanged, compared to its average volume of 635,451. Invivyd has a twelve month low of $0.69 and a twelve month high of $5.20. The firm has a fifty day moving average of $0.97 and a two-hundred day moving average of $1.25. The stock has a market cap of $84.51 million, a price-to-earnings ratio of -0.36 and a beta of 0.65.
Institutional Investors Weigh In On Invivyd
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IVVD. SG Americas Securities LLC acquired a new stake in shares of Invivyd during the 1st quarter worth approximately $56,000. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the 3rd quarter worth approximately $27,000. Tidal Investments LLC acquired a new stake in shares of Invivyd during the 1st quarter worth approximately $126,000. XTX Topco Ltd grew its position in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after buying an additional 15,376 shares during the period. Finally, Cornercap Investment Counsel Inc. bought a new position in Invivyd during the 2nd quarter worth approximately $86,000. Institutional investors and hedge funds own 70.36% of the company's stock.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
See Also
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
